PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-22.03%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-22.30%
Negative net income growth while AXSM stands at 35.33%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.29%
Negative EPS growth while AXSM is at 38.71%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.29%
Negative diluted EPS growth while AXSM is at 38.71%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-72.45%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22389.18%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
42.89%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
64.68%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-7255.64%
Negative 10Y net income/share CAGR while AXSM is at 30.77%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-121.67%
Negative 5Y net income/share CAGR while AXSM is 30.77%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
22.78%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
5223.15%
10Y equity/share CAGR above 1.5x AXSM's 290.38%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
855.06%
5Y equity/share CAGR above 1.5x AXSM's 290.38%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
-50.27%
Negative 3Y equity/share growth while AXSM is at 296.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.46%
Positive asset growth while AXSM is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
59.08%
Positive BV/share change while AXSM is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D growth drastically higher vs. AXSM's 5.75%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
40.35%
SG&A growth well above AXSM's 23.61%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.